Greenwich LifeSciences/$GLSI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Greenwich LifeSciences
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9-amino-acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including breast cancers at low (1+), intermediate (2+), and high (3+ or overexpressing) levels.
Ticker
$GLSI
Sector
Primary listing
Employees
-
Headquarters
Website
GLSI Metrics
BasicAdvanced
$291m
-
-$1.60
1.38
-
Price and volume
Market cap
$291m
Beta
1.38
52-week high
$34.10
52-week low
$7.78
Average daily volume
160k
Financial strength
Current ratio
2.007
Quick ratio
2.007
Profitability
EBITDA (TTM)
-22.404
Management effectiveness
Return on assets (TTM)
-211.27%
Return on equity (TTM)
-676.66%
Valuation
Price to book
55.1
Price to tangible book (TTM)
55.1
Price to free cash flow (TTM)
-21.507
Free cash flow yield (TTM)
-4.65%
Free cash flow per share (TTM)
-0.921
Growth
Earnings per share change (TTM)
18.75%
3-year earnings per share growth (CAGR)
37.24%
What the Analysts think about GLSI
Analyst ratings (Buy, Hold, Sell) for Greenwich LifeSciences stock.
GLSI Financial Performance
Revenues and expenses
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.